tiprankstipranks
Evolent Health Inc. (EVH)
NYSE:EVH
US Market
Want to see EVH full AI Analyst Report?

Evolent Health (EVH) Earnings Dates, Call Summary & Reports

749 Followers

Earnings Data

Report Date
Aug 05, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.01
Last Year’s EPS
-0.1
Same Quarter Last Year
Based on 14 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:May 07, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call conveyed a generally constructive operational picture: solid sequential revenue growth (ex-ECP), strong Performance Suite momentum with marquee client launches and two large new contracts, MER improvement, and continued AI automation progress. Counterbalancing these positives are meaningful near-term headwinds tied to exchange membership declines, temporary servicing and reserve-related cost pressures, a notable sequential decline in Specialty Tech & Services revenue, and elevated net leverage. Management reiterated full-year guidance and outlined expectations for MER peaking in Q3 with improving EBITDA cadence thereafter, signaling confidence in execution while acknowledging near-term uncertainty tied to exchange disenrollment and launch reserves.
Company Guidance
Evolent reiterated full‑year 2026 guidance of $2.4–$2.6 billion revenue and $110–$140 million adjusted EBITDA, with an estimated medical expense ratio (MER) of approximately 93% for the year (Q1 MER was 93%, an improvement of ~150 bps vs. Q4‑2025 excl. ECP); Q1 results included $496 million total revenue (+9% sequential excl. ECP), $22 million adjusted EBITDA, Performance Suite revenue of $323 million (+26% seq. excl. ECP), Specialty Tech & Services $81 million (‑16% seq.), and Administrative Services $92 million (‑11% q/q). The company reiterated its assumption of ~40% exchange membership decline in Specialty P&S baked into guidance, expects MER to peak in Q3 (Highmark reserve build) then improve through year‑end, and outlined a quarterly EBITDA cadence with Q2 ~in line with Q1 and $10–$15 million sequential improvements in Q3 and Q4. Financial and cash metrics include adjusted cost of revenue plus adjusted SG&A of $173 million in Q1 and ~ $675 million forecast for the year, unrestricted cash of $142 million, net debt of $792 million (no maturities until 2029), expected operating cash flow of $10–$20 million for 2026 after ~ $60 million of cash interest, and $25–$30 million in software development and capex.
Total Revenue and Sequential Growth
Q1 total revenue of $496 million, representing 9% sequential growth versus Q4 2025 (ex-ECP).
Adjusted EBITDA In Line With Expectations
Adjusted EBITDA of $22 million for Q1, consistent with guidance and the outlook provided in February.
Performance Suite Momentum
Performance Suite revenue of $323 million, up 26% sequentially versus Q4 2025 (ex-ECP); successful new launches with Aetna (Jan 1) and Highmark (May 1) with early clinical intervention and provider engagement metrics tracking above internal targets.
Major New Contracts and Cross-Sell Success
Announced two new Performance Suite deals: an advanced imaging contract covering 4.5 million lives (expected Q3 go-live) and an oncology/cardiology expansion expected to generate >$200 million of annual revenue (expected Q3 go-live), demonstrating cross-sell and platform integration strength.
Medical Expense Ratio Improvement and Full-Year Guidance
Q1 MER of ~93%, improving ~150 basis points versus Q4 2025 (ex-ECP). Reiterated full-year 2026 guidance: revenue $2.4B–$2.6B, adjusted EBITDA $110M–$140M, and estimated MER ~93%.
AI and Automation Progress
Continued AI/automation deployment with goal to auto-improve ~80% of authorization volume; initial imaging AI rollouts drove auto approvals up in the high teens and in some cases up to ~30% with minimal clinical value loss.
Balance Sheet and Liquidity Position
Unrestricted cash of $142 million at quarter end and no debt maturities until 2029, with a stated path to deleveraging.
Operational Efficiency Initiatives
Adjusted cost of revenue (ex-medical claims) plus adjusted SG&A was $173 million for Q1; company expects approx. $675 million for the year and is tracking efficiency initiatives that should moderate elevated exchange-related costs.

Evolent Health (EVH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

EVH Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 05, 2026
2026 (Q2)
-0.01 / -
-0.1
May 07, 2026
2026 (Q1)
-0.05 / -0.02
0.06-133.33% (-0.08)
Feb 24, 2026
2025 (Q4)
0.05 / 0.08
-0.02500.00% (+0.10)
Nov 06, 2025
2025 (Q3)
0.10 / 0.05
0.0425.00% (+0.01)
Aug 07, 2025
2025 (Q2)
0.07 / -0.10
0.3-133.33% (-0.40)
May 08, 2025
2025 (Q1)
0.09 / 0.06
0.34-82.35% (-0.28)
Feb 20, 2025
2024 (Q4)
0.03 / -0.02
0.23-108.70% (-0.25)
Nov 07, 2024
2024 (Q3)
0.31 / 0.04
0.3-86.67% (-0.26)
Aug 08, 2024
2024 (Q2)
0.24 / 0.30
0.14114.29% (+0.16)
May 09, 2024
2024 (Q1)
0.24 / 0.34
0.2161.90% (+0.13)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

EVH Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 07, 2026
$3.83$4.27+11.49%
Feb 24, 2026
$2.56$3.14+22.66%
Nov 06, 2025
$6.00$4.96-17.33%
Aug 07, 2025
$9.69$9.00-7.12%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Evolent Health Inc. (EVH) report earnings?
Evolent Health Inc. (EVH) is schdueled to report earning on Aug 05, 2026, After Close (Confirmed).
    What is Evolent Health Inc. (EVH) earnings time?
    Evolent Health Inc. (EVH) earnings time is at Aug 05, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is EVH EPS forecast?
          EVH EPS forecast for the fiscal quarter 2026 (Q2) is -0.01.